Skip to main content
Retour
Watch Compare

Lyell Immunopharma, Inc.

Qualité des données : 100%
LYEL
Nasdaq Manufacturing Chemicals
23,86 €
▲ 0,95 € (4,15%)
Cap. Boursière: 556,62 M
Prix
23,86 €
Cap. Boursière
556,62 M
Fourchette du Jour
22,85 € — 24,18 €
Fourchette 52 Semaines
7,65 € — 45,00 €
Volume
81 691
Ouverture 23,76 €
Moyenne 50J / 200J
22,83 €
4,51% above
Moyenne 50J / 200J
18,63 €
28,07% above

Quick Summary

Points Clés

Revenue declined -75,89% annually over 5 years
Negative free cash flow of -150,80 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 34,91%
Capital intensive — 2166,67% of revenue goes to capex

Croissance

Revenue Growth (5Y)
-75,89%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)-40,98%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-87,40%
En dessous de la moyenne du secteur (-53,47%)
ROIC-58,74%
Net Margin-762355,56%
Op. Margin-748344,44%

Sécurité

Debt / Equity
N/A
Current Ratio10,30
Interest CoverageN/A

Valorisation

PE (TTM)
-2,03
En dessous de la moyenne du secteur (-1,47)
P/B Ratio1,69
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -2,0 -1,5
P/B 1,7 1,6
ROE % -87,4 -53,5
Net Margin % -762355,6 -41,5
Rev Growth 5Y % -75,9 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -40,98% Revenue Growth (3Y) -47,38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -75,89% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 36 000,0 Net Income (TTM) -274,45 M
ROE -87,40% ROA -69,18%
Gross Margin N/A Operating Margin -748344,44%
Net Margin -762355,56% Free Cash Flow (TTM) -150,80 M
ROIC -58,74% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10,30
Interest Coverage N/A Asset Turnover 0,00
Working Capital 296,32 M Tangible Book Value 329,12 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,03 Forward P/E N/A
P/B Ratio 1,69 P/S Ratio 15461,54
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -27,09%
Market Cap 556,62 M Enterprise Value 433,04 M
Per Share
EPS (Diluted TTM) -16,06 Revenue / Share 0,00
FCF / Share -6,46 OCF / Share -6,43
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2166,67% FCF Conversion 54,95%
SBC-Adj. FCF -174,69 M Growth Momentum 34,91

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 36 000,0 61 000,0 130 000,0 84,68 M 10,65 M
Net Income -274,45 M -342,99 M -234,63 M -183,12 M -250,22 M
EPS (Diluted) -16,06 -1,31 -0,93 -0,74 -1,84
Gross Profit — — — — —
Operating Income -269,40 M -358,76 M -247,01 M -187,06 M -214,78 M
EBITDA — — — — —
R&D Expenses — — 182,95 M 159,19 M 138,69 M
SG&A Expenses — — — — —
D&A 11,54 M 19,63 M 20,25 M 18,02 M 13,62 M
Interest Expense — — — — —
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 340,05 M 490,86 M 750,03 M 937,56 M 1,13 B
Total Liabilities 91,85 M 108,04 M 95,08 M 104,31 M 197,62 M
Shareholders' Equity 248,20 M 382,82 M 654,95 M 833,25 M 929,79 M
Total Debt — — — — —
Cash & Equivalents 60,18 M 105,60 M 145,65 M 123,55 M 293,83 M
Current Assets 260,94 M 379,59 M 554,69 M 651,30 M 626,29 M
Current Liabilities 49,41 M 53,79 M 34,52 M 37,03 M 46,74 M